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Background: Molecular biology has recently added new insights into the
comprehension of the physiopathology of the medullary sponge kidney disease
(MSK), a rare kidney malformation featuring nephrocalcinosis and recurrent renal stones.
Pathogenesis and metabolic alterations associated to this disorder have been only
partially elucidated.
Methods: Plasma and urine samples were collected from 15 MSK patients and 15
controls affected by idiopathic calcium nephrolithiasis (ICN). Plasma metabolomic profile
of 7 MSK and 8 ICN patients was performed by liquid chromatography combined with
electrospray ionization tandemmass spectrometry (UHPLC–ESI-MS/MS). Subsequently,
we reinterrogated proteomic raw data previously obtained from urinary microvesicles of
MSK and ICN focusing on proteins associated with sphingomyelin metabolism. Omics
results were validated by ELISA in the entire patients’ cohort.
Results: Thirteen metabolites were able to discriminate MSK from ICN (7 increased
and 6 decreased in MSK vs. ICN). Sphingomyelin reached the top level of discrimination
between the two study groups (FC: −1.8, p < 0.001). Ectonucleotide pyrophophatase
phosphodiesterase 6 (ENPP6) and osteopontin (SPP1) resulted the most significant
deregulated urinary proteins in MSK vs. ICN (p < 0.001). ENPP6 resulted up-regulated
also in plasma of MSK by ELISA.
Conclusion: Our data revealed a specific high-throughput metabolomics signature of
MSK and indicated a pivotal biological role of sphingomyelin in this disease.
Keywords: medullary sponge kidney, idiopathic calcium nephrolithiasis, metabolomics, sphingomyelin,
proteomics
INTRODUCTION
Medullary sponge kidney disease (MSK) is a kidney malformation with a rare frequency in the
general population but relatively common in renal stone formers (1). This clinical condition
is associated with nephrocalcinosis and renal stones, urinary acidification and concentration
alterations, and cysts formation in the precalyceal ducts (1). Its pathogenesis is complex and not
fully understood.
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MSK development in childhood and its relationship with
developmental disorders (e.g., congenital hemihypertrophy and
Beckwith–Wiedemann syndrome) and with kidney anomalies
(e.g., horse-shoe kidney, unilateral renal aplasia, contralateral
congenital small kidney) (2–4) support the hypothesis of
an inherited condition. Genetic studies revealed that familial
clustering of MSK is common and has an autosomal dominant
inheritance with a reduced penetrance and variable expressivity
(5, 6). Additionally, mutations in the glial cell line-derived
neurotrophic factor (GDNF) and receptor tyrosine kinase (RET)
genes, disrupting the “ureteric bud–metanephric mesenchyme”
interface, could be responsible of the disease pathogenesis (7, 8).
Moreover, as demonstrated by urinary proteomic analysis,
some regulators of epithelial cell differentiation, kidney
development, cell migration/adhesion, extracellular matrix
organization, and complement may be deregulated in MSK
and could serve as non-invasive MSK diagnostic biomarkers
(9, 10). Among them laminin subunit alpha 2 (LAMA-2) seems a
good candidate.
Laminin, a family of at least 15 αβγ heterotrimeric proteins of
the extracellular matrix and a major constituent of the basement
membrane (11), mediates the attachment, migration, and
organization of cells into tissues during embryonic development
by interacting with other extracellular matrix components.
Additionally, laminin may have a role in the cysts’ formation
being responsible of cellular apical pole orientation (12–14).
LAMA-2 and other selected proteins could be proposed as
diagnostic biomarkers to replace invasive procedures or imaging
techniques with low sensitivity (e.g., Intravenous Urography and
CT urography).
A subsequent analysis of the protein content of
microvesicles/exosomes isolated from urine of MSK and
idiopathic calcium nephrolithiasis (ICN) patients identified
a core panel of 20 proteins that distinguished the two study
groups (15). Among them, three exosome proteins involved in
the lectin complement pathway maximized the discrimination
between MSK and ICN: Ficolin 1, Mannan-binding lectin serine
protease 2 and Complement component 4-binding protein β.
This revealed, for the first time, a possible involvement of the
complement pathway in MSK. In particular the downregulation
of MASP2 together with the upregulation of C4BPB that inhibits
the activation of the complement cascade by preventing the
formation of the classical C3 and C5 convertases, may reflect the
physiological attempt of the kidneys to mitigate the activation
of the lectin complement pathway, also to preserve renal
function. Indeed, the hyperactivation of complement may induce
glomerular and tubulointerstitial injury (16).
Additionally, our group has recently described extra-renal
alterations involving the cardiovascular apparatus, the central
nervous system, and bone metabolism (17, 18) in MSK
patients suggesting that it may be considered a systemic
disease. These patients are more prone to develop hypertrophic
cardiomyopathy with adipose metaplasia and mitral valve
prolapse and bone mineralization defects.
Therefore, to obtain additional information on the molecular
mechanisms underlying MSK and to discover systemic factors
of this disease, we used an untargeted approach to compare
TABLE 1 | Main demographic and clinical characteristics of the patients.
MSK ICN p
(n = 15) (n = 15)
Males, n (%) 10 (66.7) 8 (53.3) 0.709
Age, years, mean (SD) 55.80 (15.50) 57.33 (14.80) 0.784
Serum creatinine, mg/dL, mean (SD) 0.86 (0.17) 0.82 (0.12) 0.420
Urinary Ca, mg/die, mean (SD) 317 (107) 222 (107) 0.045
Urinary protein, mg/dL, median (IQR) 0.11 (0.06, 0.13) 0.09 (0.00, 0.15) 0.835
Urinary volume, ml/die, mean (SD) 2136 (450) 1635 (542) 0.026
the plasma metabolomic profile of MSK vs. idiopathic calcium
nephrolithiasis (ICN) patients, used as control group, and we
reinterrogated proteomic raw data previously obtained from
urinary microvesicles of MSK and ICN (15) focusing on proteins
associated with sphingomyelin metabolism.
MATERIALS AND METHODS
Patients
A total of 15 adult patients with medullary sponge kidney disease
(MSK) and 15 with idiopathic calcium nephrolithiasis (ICN)
matched for age, gender, and geographical origin followed up at
Renal Unit of University/Hospital of Verona were included in the
study. The main demographic and clinical characteristics of the
patients have been reported in Table 1.
The inclusion criteria for the MSK group were the same
as described in our previous study (9). Particularly, patients
had both kidneys involved, nephrocalcinosis and/or cysts in
at least 2 papillae in each kidney. For MSK, patients had
papillary precalyceal ectasias on films obtained at least 10min
after contrast medium injection in the absence of compression
maneuvers and signs of obstruction. The X-ray films were
reviewed by an independent radiologist to confirm the diagnosis.
For ICN patients the inclusion criteria were as follows:
calcium stone disease, normal serum creatinine and electrolyte
concentrations, and urinary pH≤ 5.5 measured in spot morning
urine (after overnight fasting) to exclude tubular acidosis. Major
exclusion criteria for ICN were as follows: the presence of
endocrine diseases and cystic kidney disorders, nephrocalcinosis,
and obstructive nephropathy.
Plasma and urine samples were obtained from all patients
enrolled in the study. Whole-blood samples were collected in
EDTA-coated tubes. The tubes were centrifuged (1,800 × g for
10min), and the plasma was extracted and aliquoted. Second
morning urine were collected and centrifuged to eliminate cells
and debris. The supernatants were divided into aliquots and
stored at−80◦C until use.
Laboratory data were electronically registered for all
patients enrolled. All subjects gave their informed consent for
inclusion before they participated in the study. The study was
conducted in accordance with the Declaration of Helsinki,
and the protocol was approved by the Local Ethics Committee
(AOUI Verona, 1312CESC).
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Sample Preparation and Set-Up for
Metabolomics
Plasma samples from 7 MSK patients and 8 controls affected
by idiopathic calcium nephrolithiasis (ICN) were used for
metabolomics using liquid chromatography combined with
electrospray ionization tandem mass spectrometry (UHPLC–
ESI-MS/MS).
Sample preparation was performed according to standard
protocols (19). MS setup: plasma metabolites were detected using
liquid chromatography combined with electrospray ionization
tandem mass spectrometry (HPLC–ESI-MS/MS). The analytic
system consists of an Accela 1250 pump, Accela autosampler
and a LTQOrbitrap Velos mass spectrometer (Thermo Scientific,
USA). The analytes were separated on Kinetex C18 100mm ×
2.1mm× 1.7 um and mobile phase [solvent A: aqueous solution
of acetic acid (pH 2); solvent B: methanol] in gradient elution
at a flow rate of 300 ul/min. The HPLC elution program was
as follows: 5% B (2Min), 30% B (linear increase in 1Min),
30% B (5Min), 5% B (linear decrease in 1min), 5% B (3min).
The column temperature was maintained at 25◦C. The injection
volume was 5 ul. The metabolites were detected both in the
positive (ESI+) and in the negative (ESI –) ionization mode (20).
Processing of Raw Data
Raw mass spectrometry (MS) files were processed using XCMS
software version 3.2.7.1. Features were associated with known
metabolites, when possible, searching their M/Z and RT values
in the Metlin data base. Features presenting a missing value rate
>20% were removed. Variables showing a poor variation in their
values and outlier values were removed through a filtering based
on Inter Quartile Range (IQR). Each feature was normalized
by median-normalization and scaled by Auto scaling (mean-
centered and divided by the standard deviation of each variable)
(21). Statistical analyses were performed with MetaboAnalyst
software version 4.0 (22).
ELISA
The concentration of sphingomyelin in plasma and urine, of
the entire cohort of patients was determined by ELISA (Abcam,
AB133118 and LifeSpan BioScience, LS-F30127) following the
protocols provided by the manufacturer. ELISA kits were also
used to measure the content of SPP1 and ENPP6 (Abcam,
ab100618 and MyBiosource, MBS9327272).
Statistical and Bioinformatics Analyses
For ELISA data analysis, U-Mann-Whitney test was used to assess
differences in the protein levels of sphingomyelin, SPP1 and
ENPP6 between the 2 study groups. Results were expressed as
median and IQ range. A value of P < 0.05 was considered to be
statistically significant.
For metabolomics, differences in feature mean values between
paired samples (i.e., pre and post run) were tested by estimating
a fold-change value between groups and an associated p-value.
Dysregulated features (fold change ≥ 1.5 and nominal p ≤
0.05, arbitrarily chosen) were plotted in a Cloud plot, reporting
intensities of signals between groups.
For t-test analysis p-values were adjusted for multiple testing
using the Benjamini-Hochberg false discovery rate. Principal
component analysis (PCA) was used to explore the data and
identify any possible resemblances among subjects, based on the
value of all features. Statistical analysis of metabolite-associated
features was performed using XCMS and MetaboAnalyst
(v.4.0) (22).
Enrichment analysis of the biological process was performed
using information of the Kegg database.
For urine proteomic analysis, we have re-interrogated our
previous proteomic datasets obtained from whole urinary and
urinary microvesicles isolated from 15 MSK and 15 ICN (9, 15).
In particular, mass spectrometry data were analyzed as
previously reported (15). Then, the fold change of the identified
proteins associated to the sphingomyelin metabolism (23–25)
and their −Log10 P-values were visualized in a volcano plot.
The proteomic profile, after Z-score normalization, of these
associated proteins were visualized by Heatmap diagram. Finally,
Support Vector Machine (SVM) was used to identify a rank
list of sphingomyelin metabolism proteins for discrimination
between MSK and ICN samples. Proteins were considered to be
significantly differentially expressed between the two conditions
with power of 80% and an adjusted P ≤ 0.05 in the T-test after
correction for multiple interactions (Benjamini-Hochberg) and
a fold change of ≥2. In addition, the proteins needed to show
at least 70% identity in the samples in one of two conditions.
In SVM a 4-fold cross-validation approach was applied to
estimate the prediction and classification accuracy of ranked
list of statistically significant proteins. All proteomic statistical
analysis were performed using OriginLab and the latest version
of software package R available at the time of the experiments.
RESULTS
Metabolomic Profiling Discriminated MSK
From ICN Patients
After missing values estimation, 4,005 signals have been obtained
and subjected to statistical analysis. Thirteen metabolites were
able to clearly discriminate MSK from ICN (7 metabolites
increased and 6 decreased in MSK compared to ICN patients)
(Figure 1A). Using the principal Component Analysis (PCA)
plot of the selected 13 metabolites, it was possible to clearly
differentiate MSK from ICN (Figure 1B).
Sphingomyelin, which level was significantly decreased in
MSK vs. ICN, reached the higher level of discrimination between
the two study groups (Log2 fold change:−1.8, p < 0.001).
ELISA for Sphingomyelin Confirmed
Metabolomics Results
To validate metabolomics data, we performed ELISA on plasma
samples collected from all enrolled patients (15 MSK and
15 ICN).
Data analysis clearly demonstrated that the level of
sphingomyelin was significantly lower in MSK patients than in
ICN [Median/(IQR) MSK vs. ICN, 28.33 (12.73, 30.76) vs. 36.52
(33.48, 41.67), p < 0.01] (Figure 2A). ROC curve showed that
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FIGURE 1 | 2-D Supervised hierarchical clustering and Principal Component Analysis (PCA) discriminating MSK from ICN patients. (A) 2-D Supervised hierarchical
clustering able to discriminate patients with Medullary Sponge Kidney (MSK) from controls (ICN, nephrolithiasis). Patients are represented as vertical columns, with red
symbols indicating MSK patients (n = 7) and green symbols ICN (n = 8). Thirteen metabolites (rows) were used for hierarchical grouping. The scale intensity of the
metabolites is depicted according to the color key shown on the right. Red indicates high intensity level; blue, low intensity level. The figure also shows the mean levels
of the fold change of expression of each metabolite in the MSK group compared to controls. (B) PCA plot built using the 13 metabolites selected by statistical analysis
showed high discrimination accuracy between the two study groups.
the level of sphingomyelin can discriminate MSK from ICN
patients (Figure 2B). The AUC, 95% CI and p values for the ROC
analysis were 0.913, 0.808–1.000, and p < 0.001, respectively.
The cutoff, sensitivity, specificity were 31.5 mg/dl, 87%,
87%, respectively.
To confirm whether sphingomyelin was reduced also in
kidney, we decided to measure its urinary level by ELISA in MSK
and ICN patients.
According to the results obtained in plasma, the level of
sphingomyelin in urine was lower in MSK patients than in
ICN (Figure 3A) [Median/(IQR) MSK vs. ICN, 1.13(1.08–
1.21) ng/ml vs. 1.25 (1.23–1.31) ng/ml p < 0.0001]. The
AUC, 95% CI and p values in ROC analysis were 0.960,
0.902–1.000, and p < 0.001, respectively (Figure 3B).
The cutoff, sensitivity, specificity were 1.2 ng/ml, 93%,
87% respectively.
Proteomic Profile of Urinary Microvesicles
Differentiated MSK From ICN
The analysis of urinary proteomic data of MSK and
ICN focused on proteins associated with sphingomyelin
metabolism did not show any statistically significant difference
(Supplementary Methods and Supplementary Figure 1).
Then, since microvesicles seem to be involved
in the complex biological machinery associated
with MSK (15) and appear highly enriched in
sphingomyelin (26), we decided to re-interrogate
proteomic raw data previously obtained (15) from urinary
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FIGURE 2 | ELISA for sphingomyelin validated metabolomic results. (A) Dot plot shows sphingomyelin plasma levels (mg/dl) in 15 patients with MSK (green) and 15
with nephrolithiasis (ICN, red). Solid lines indicate median values. The p value was calculated using the t-test. (B) ROC curve analysis of plasma sphingomyelin
revealed that the reported values allow to discriminate MSK from the ICN.
FIGURE 3 | ELISA for the urinary content of sphingomyelin was in accordance with the results obtained in plasma. (A) Dot plot shows sphingomyelin urinary levels
(ng/ml) measured in 15 patients with MSK and 15 with ICN. Solid lines indicate median values. The p value was calculated using the U Mann-Whitney test. (B) ROC
curve analysis of urinary sphingomyelin revealed that the reported values allow to discriminate MSK from the ICN.
microvesicles isolated from MSK and ICN focusing
on proteins associated with sphingomyelin metabolism
(Supplementary Methods).
As shown in Figure 4, twenty-nine proteins associated to
sphingomyelin metabolism were identified. Among these,
14 proteins were able to discriminate MSK from ICN
patients. SPP1 (Osteopontin) and ENPP6 (Ectonucleotide
Pyrophosphatase/Phosphodiesterase 6), two proteins
involved in renal morphogenesis, were the top de-regulated
proteins identified by the SVM to distinguish between
urinary microvesicles isolated from MSK and ICN. In
particular, SPP1, in four isoforms (2, 3, 4, and 5) appeared
over-expressed, while ENPP6 under-expressed in MSK
compared to ICN (Figures 4A,B). ENPP6 down-regulation
in MSK was also confirmed by urinary ELISA (Figure 5).
Instead, SPP1 levels did not reach statistical differences
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FIGURE 4 | Proteomic profile. (A) Heatmap of the 29 proteins associated to sphingomyelin metabolism identified in urinary microvesicles of MSK and ICN patients.
Each row represents a protein and each column a sample. Normalized Z-scores of protein abundance are depicted using a pseudocolor scale (red, white, and blue
indicating positive equal and negative expression, respectively) compared to each protein value. The dendrogram displays unsupervised hierarchical clustering
analysis. Similar sample/proteome-profile values are next to each other. (B) Volcano plot of the 29 proteins associated to sphingomyelin metabolism. The plot is based
on the relative abundance ratio (log2 fold change) and the p value (−log10). Gray, red and blue circles indicate the changes for the non-significant, significant up and
down regulated proteins in MSK samples. Black line indicates the limits of statistically significant.
FIGURE 5 | ELISA for the urinary content of ENPP6 confirmed proteomics results. (A) Box plot shows ENPP6 urinary levels (pg/ml) measured in 15 patients with MSK
and 15 with ICN. Solid lines indicate median values. The p value was calculated using the U Mann-Whitney test. (B) ROC curve analysis of urinary ENPP6 revealed
that the reported values allow to discriminate MSK from the ICN.
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FIGURE 6 | Quantification of ENPP6 and SPP1 by ELISA. Box plots revealed (A) higher level of ENPP6 (ng/ml) in ICN vs. MSK and (B) no significant difference in the
level of SPP1 (ng/ml) in plasma of MSK and ICN. The p values were calculated using the t-test. (C) Analysis of the ROC curve for plasma ENPP6 and SPP1.
in MSK vs. ICN (see whole urinary proteomics results
in Supplementary Figure 1).
ELISA Demonstrated Low Levels of ENPP6
in Plasma of MSK vs. ICN Patients
Statistical analysis showed that the ENPP6 was under-expressed
in plasma of patients with MSK compared to ICN (controls)
[Median/(IQR) MSK vs. ICN, 0.9 (0.8, 1.1) vs. 1.2 (1.0, 1.5), p
= 0.017]. ROC analysis revealed the power of discrimination of
this biological factor (Figure 6A). The AUC, 95% CI and p-values
for the ROC analysis were 0.756, 0.578–0.933, and p = 0.009,
respectively. The cutoff, sensitivity, specificity were 0.93 ng/ml,
87%, 60% respectively.
Contrarily, no difference was found at plasma level in SPP1
between the two groups [Median/(IQR) MSK vs. ICN, 7.06
(6.18, 10.00) vs. 7.34 (5.93, 9.48), p = 0.663] (Figure 6B). The
AUC and 95% CI for the ROC analysis were 0.453, 0.238–
0.668. The cutoff, sensitivity, specificity were 5.3 ng/ml, 93%,
27% respectively (Figure 6C).
DISCUSSION
This study demonstrated, for the first time, the involvement
of the sphingolipid metabolic pathway in medullary sponge
kidney (MSK) disease pathogenesis and offered new insights
into the biological machinery associated with this complex and
neglected disorder.
Results of our omics research strategy
revealed that several metabolites (sphingomyelin,
phosphatidylcholine, lysophosphatidylethanolamine, citrulline,
lysophosphatidylcholine, Ganglioside GA2, diglyceride, 2-
Hexaprenyl-6-methoxy-1,4-benzoquinol) were able to clearly
discriminate MSK from ICN. Sphingomyelin, a sphingolipid
and major component of mammalian cells, resulted the
most down-regulated.
Sphingomyelin can be synthesized from ceramide by
sphingomyelin synthase (SMS) types 1 and 2 (27). SMS1 is
constitutively expressed in the Golgi apparatus and is involved
in the homeostatic synthesis of SM (28), while the expression
of SMS2 in the Golgi depends on numerous stimuli (29).
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The reverse process of sphingomyelin hydrolysis to ceramide
and phosphorylcholine is induced by different isoforms of
sphingomyelinase and represents an alternative route for the
synthesis of ceramide (30).
At our knowledge, this is the first report describing a specific
metabolic fingerprint of MSK and the possible involvement of
sphingomyelin in the MSK-associated biological impairment.
Instead, alterations in the metabolism of sphingomyelin and
other sphingolipids have been extensively reported in other
diseases including neurodegenerative [Alzheimer’s disease (31),
Parkinson’s (32), multiple sclerosis (33), Lewy body dementia
(34)], vascular (35), and bone disorders (30).
Sphingomyelin and ceramide are implicated in the
survival of osteoclasts (36) and in the mineralization of the
extracellular matrix. As demonstrated in animal models, a
neutral Sphingomyelinase 2 deficiency is responsible for defects
in bone and dental mineralization, probably due to deficiencies
in ceramide and phosphocholine synthesis secondary to the
degradation of sphingomyelin (37).
The involvement of sphingomyelin in MSK could partially
explain the pathogenesis of systemic alterations observed in
these patients. MSK patients, in fact, seem to have an altered
neuroprotection capability against oxidative stress/ischemia
and several bone metabolic defects (17, 18). As previously
reported by our group, some MSK patients may develop central
nervous system alterations (17) with the genetic derangement
of the RET–GDNF axis having a possible pathogenetic role
(38). Sphingomyelin, involved in several neurodegenerative
disorders (39), may also contribute to the development of these
clinical features.
As previously pointed out, about 75% of patients with MSK
have alterations in bone mineralization (60% osteopenia and
about 15% osteoporosis) in the absence of common risk factors
such as menopause or hyperparathyroidism and also due to the
persistent hypercalciuria (18). This high secretion of calciummay
be the result of the renal calcium-handling defect (1), absorptive
hypercalciuria (40), and defective urinary acidification (41) that
characterize these patients.
The reduction of sphingomyelin, observed in MSK patients,
could represent an adaptive response of the bone tissue to
modulate osteoblastic/osteoclastic activity in the presence of a
negative calcium balance and altered tubular acidification typical
changes in the kidneys of these patients.
Sphingomyelin and some of its associated proteins, enriched
inmicrovesicles [characterized by a high content of sphingolipids
(42)] resulted also deregulated in the urines of our MSK
patients demonstrating a possible ubiquitously alteration of this
pathway in these patients. The absence of statistical difference
in the level of the proteins associated with sphingomyelin
metabolism in whole urinary proteomics may be due to
the fact that it is mainly synthesized/compartmentalized
in Golgi by the biological/biochemical machinery of the
renal epithelial tubular cells and then, probably, excreted
in urine. Additionally, we cannot exclude that part of the
sphingomyelin detected in urine by ELISA could derive from
plasma. Further studies are necessary to better understand
this issue.
Interestingly, ectonucleotide pyrophophatase
phosphodiesterase 6 (ENPP6) and osteopontin (SPP1) resulted
the most down- and high-regulated protein, respectively.
ENPP6 belongs to a family of 7 phosphodiesterases
involved in multiple cellular processes. ENPP6 hydrolyzes
only choline-containing lysophospholipids to phosphocholine
and monoacylglyceride (43). It is expressed in multiple tissues
including the heart, central nervous system, kidney and bone
tissue. In the kidney it is mostly expressed on the luminal side of
proximal tubular epithelial cells. It is possible that ENPP6 in the
kidney contributes to the reabsorption of choline by hydrolyzing
glycerophosphocholine in the primary urine (43).
ENPP6, then, would participate in the synthesis of inorganic
phosphate, a constituent of the bone matrix, through the
metabolism of phosphocholine (44) and its higher level in ICN
could predispose these patients to stone forming (45).
SPP1 is a widely expressed and multifunctional
phosphorylated acid glycoprotein, it regulates the synthesis
of bone matrix and the activity of osteoclasts. Osteopontin
increases bone resorption by stimulating osteoclastogenesis
and by anchoring osteoclasts to the matrix (46, 47). SPP1 in
physiological conditions is expressed in the distal nephron,
especially at the level of the thick segment of the loop of Henle.
In humans, there is an increased expression of osteopontin in
the urine in several kidney diseases: hypertensive nephropathy,
renal carcinoma, membranous glomerulonephritis, IgA
nephropathy, lupus nephritis and in mouse models of ADPKD.
In addition, high expression of osteopontin in urine from
MSK has been already reported by our group (48). Then, Ricci
et al., have described a similar up-regulation in a group of
pediatric patients suffering from ADTKD (Autosomal dominant
Tubulointerstitial Kidney Disease) associated with a mutation
of HNF1B, a hereditary tubulointerstitial nephritis with cystic
dilatation of the renal tubules (49) and in kidney from rat model
of ADPKD (50). It is possible that this protein could mediate the
cyst formation inMSK patients similarly to ADPKD. The absence
of a significant difference in its plasma level in our MSK vs. ICN
patients could be explained by a possible paracrine urinary effect
of this protein in MSK.
Therefore, our study, although performed on a small
cohort of patients (particularly in metabolomics), highlighted
a specific metabolic profile associated with MSK and
confirmed our hypothesis that this disease could have
systemic implications. Sphingomyelin, then, could represent
a new disease pathogenetic element and a potential novel
biomarker or therapeutic target. Further studies that
could employ urinary metabolomics and in vitro/in vivo
functional experiments, need to be undertaken to validate our
research hypothesis and to translate our results into the daily
clinical practice.
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